Medivation, Inc.

Imperative And Execution At the end of May 2024, the NASDAQ Biotech Index (NBI) fell into negative territory both in the year to date and compared with the previous 12 months. This was despite the imp

NICE, the body that makes reimbursement recommendations for England’s National Health Service, has given the thumbs down to Pfizer Inc. ’s PARP inhibitor Talzenna (talazoparib) for the treatment of c

The top 11 Japanese pharmaceutical firms have relatively higher R&D success rates in the US market in the areas of oncology and central nervous system (CNS), a new report from Citeline's Biomedtracke

For many struggling researchers-turned-CEOs of Japanese bioventures, 81-year-old Dr Toichi Takenaka has been a mentor to whom they can make a phone call for any advice. After a string of successful dr